Haematologica, Vol 92, Issue 2, 277-278 doi:10.3324/haematol.10618
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schilthuizen, C.
Right arrow Articles by Sonneveld, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schilthuizen, C.
Right arrow Articles by Sonneveld, P.

Multiple Myeloma

Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma

Céline Schilthuizen*, Annemiek Broyl*, Bronno van der Holt°, Yvonne de Knegt*, Henk Lokhorst@, Pieter Sonneveld*,

* From the Department of Hematology, Erasmus Medical Center, Rotterdam (EMCR), the Netherlands
° Department of Trials & Statistics-HOVON Data Center, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam (EMCR), the Netherlands
# Department of Clinical Chemistry, Erasmus Medical Center, Rotterdam (EMCR), the Netherlands
@ Department of Hematology, Utrecht University Medical Center Utrecht, 6Utrecht (UMCU), the Netherlands

Correspondence: Pieter Sonneveld, Erasmus Medical Center, Dept. of Hematology, Room L-439, Dr. Molewaterplein 40, 3000 CA Rotterdam, The Netherlands. Phone: international +31.10.4633123. Fax: international +31.10.4635814. E-mail: p.sonneveld{at}erasmusmc.nl

We investigated the role of single nucleotide polymorphisms in genes encoding for drug-metabolizing enzymes in 209 newly diagnosed multiple myeloma patients included in a clinical trial comparing single with double intensive therapy. We observed no significant association between polymorphisms in CYP3A4, CYP3A5, MDR1, GSTM1 and GSTT1 and outcome either after treatment with induction chemotherapy or after high-dose therapy.

Key words: gentic polymorphism, survival, toxicity, multiple myeloma.